Abstract
Introduction: Short bowel syndrome (SBS) is a heterogeneous condition in which patients suffer from impaired intestinal absorption due to absolute loss of the intestine. Approximately 75% of SBS cases develop after a single massive bowel resection. Patients with SBS with intestinal failure (II) [SBS-II] experience decreased quality of life and increased morbidity and mortality due to their dependence on parenteral support (PS). Teduglutide is a degradation-resistant peptide 2 (GLP-2) analog that increases the functional and structural capacity of the intestine. Objective: To analyze the scientific evidence for teduglutide in parenteral support in patients with short bowel syndrome. Methods: The systematic review rules of the PRISMA Platform were followed. The search was conducted from June to August 2024 in the Web of Science, Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 91 articles were found. 29 articles were fully evaluated and 07 were included and developed in the present systematic review study. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 20 studies with a high risk of bias and 22 studies that did not meet GRADE and AMSTAR-2. Most studies showed homogeneity in their results, with X2=82.7%>50%. It was concluded that teduglutide can restore intestinal structural and functional integrity, promote mucosal growth, reduce gastric emptying and secretion, and increase nutrient absorption and enteral independence from parenteral nutrition. The 24-week treatment time with teduglutide was generally well tolerated in patients with short bowel syndrome with intestinal failure. The clinical studies showed that teduglutide treatment reduced the volumes and number of days of parenteral support for patients with short bowel syndrome with intestinal failure.